Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Genmab A/S

Genmab (Otc) ($GMAB) announced an update on their ongoing clinical study. Genmab (OTC: GMAB) is advancing a Phase 3 study called LiGeR-CRC2 in colo...

Genmab’s Petosemtamab Trial Emerges as a New Catalyst in Colorectal Cancer

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N...

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI)

Genmab ( ($GMAB) ) has shared an announcement. On August 11, 2026, Genmab A/S announced a small increase in its share capital following the exercis...

Genmab Boosts Share Capital After Employee Warrant Exercise

We are diving into three healthcare stocks which all have a Strong Buy consensus and a 10 out of 10 TipRanks Smart Score. The Smart Score is a prop...

3 ‘Perfect Ten’ Healthcare Stocks That Analysts Rate as a Strong Buy

In a report released on August 7, Rajan Sharma from Goldman Sachs maintained a Buy rating on Genmab A/S, with a price target of $33.50. The company...

Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Genmab (GMAB), Irhythm Technologies (IRTC) and Editas Medicine (E...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GMAB	$33.60	-2.35%	1.00M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GMAB	$33.60	-2.4%	1.00M
3
4
5
6

GMAB

Get Genmab A/S Data in Excel

Get Genmab A/S Data in Excel